Review article: Updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue 1, 2006, Pages 11-25

  Helmy, A ^a,b  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b Assiut University Faculty of Medicine   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID DERIVATIVE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; AZATHIOPRINE; BLOOD CLOTTING FACTOR; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DEFIBROTIDE; GEMTUZUMAB OZOGAMICIN; GLUTATHIONE; HEPARIN; HERBACEOUS AGENT; MATRIX METALLOPROTEINASE; MERCAPTOPURINE; MONOCROTALINE; NITRIC OXIDE; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; POLYDEOXYRIBONUCLEOTIDE; TERBINAFINE; TIOGUANINE; TISSUE PLASMINOGEN ACTIVATOR; UNINDEXED DRUG; URETHAN; VASCULOTROPIN;

ABDOMINAL RADIOTHERAPY; ACUTE GRANULOCYTIC LEUKEMIA; ASCITES; BILE DUCT OBSTRUCTION; CLINICAL TRIAL; CONTRACEPTION; CONVALESCENCE; DEATH; DISEASE SEVERITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMODYNAMICS; HEPATITIS C; HEPATOMEGALY; HISTOPATHOLOGY; HUMAN; HYPERBILIRUBINEMIA; IMAGING; INCIDENCE; KIDNEY FAILURE; LABORATORY; LIVER TRANSPLANTATION; LIVER VEIN OBSTRUCTION; LUNG INSUFFICIENCY; NONHUMAN; ORGAN TRANSPLANTATION; PATHOGENESIS; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; REVIEW; RISK FACTOR; WHOLE BODY RADIATION;

ANIMALS; AZATHIOPRINE; ENDOTHELIAL CELLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPARIN; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RATS; TISSUE PLASMINOGEN ACTIVATOR; WHOLE-BODY IRRADIATION;

EID: 33644914519     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02742.x     Document Type: Review

References (182)

1. DeLeve LD Shulman HM McDonald GB Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease) Semin Liver Dis 2002 22 623 38
2. Dulley FL Kanfer EJ Appelbaum FR et al. Veno-occlusive disease of the liver after chemoradiotherapy and autologous bone marrow transplantation Transplantation 1987 43 870 3
3. Kumar S DeLeve LD Kamath PS Tefferi A Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation Mayo Clin Proc 2003 78 589 98
4. Carreras E Veno-occlusive disease of the liver after hemopoietic cell transplantation Eur J Haematol 2000 64 281 91
5. Baron F Deprez M Beguin Y The veno-occlusive disease of the liver Haematologica 1997 82 718 25
6. Wadleigh M Ho V Momtaz P Richardson P Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment Curr Opin Hematol 2003 10 451 62
7. Bras G Jeliffe DB Stuart KL Veno-occlusive disease of the liver with non-portal type of cirrhosis occurring in Jamaica Arch Pathol 1954 57 285 300
8. McFarlane AL Branday W Hepatic enlargement with ascitic children BMJ 1945 1 838 40
9. Selzer G Parker RGF Senecio poisoning exhibiting as Chiari's syndrome: a report on twelve cases Am J Pathol 1950 27 885 907
10. Willmot FC Robertson GW Senecio disease, or cirrhosis of the liver due to senecio poisoning Lancet 1920 2 848 9
11. Stuart KL Bras G Veno-occlusive disease of the liver Q J Med 1957 26 291
12. Rollins BF Hepatic veno-occlusive disease Am J Med 1986 81 297 306
13. Tandon PN Tandon RN Tandon HD et al. An epidemic of hepatic veno-occlusive disease in central India Lancet 1976 ii 271
14. Azoulay D Castaing D Lemoine A et al. Successful treatment of severe azathioprine-induced hepatic veno-occlusive disease in a kidney-transplanted patient with transjugular intrahepatic portosystemic shunt Clin Nephrol 1998 50 118 22
15. Zuckerman M Steenkamp V Stewart MJ Hepatic veno-occlusive disease as a result of a traditional remedy: confirmation of toxic pyrrolizidine alkaloids as the cause, using an in vitro technique J Clin Pathol 2002 55 676 79
16. Chojkier M Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids J Hepatol 2003 39 437 46
17. Eisenhauer T Hartmann H Rumpf KW et al. Favourable outcome of hepatic veno-occlusive disease in a renal transplant patient receiving azathioprine, treated by portacaval shunt: report of a case and review of the literature Digestion 1984 30 185 90
18. Haboubi NY Ali HH Whitwell HL et al. Role of endothelial cell injury in the spectrum of azathioprine-induced liver disease after renal transplant: light microscopy and ultrastructural observations Am J Gastroenterol 1988 83 256 61
19. Katzka DA Saul SH Jorkasky D et al. Azathioprine and hepatic venocclusive disease in renal transplant patients Gastroenterology 1986 90 446 54
20. Liano F Moreno A Matesanz R et al. Veno-occlusive hepatic disease of the liver in renal transplantation: is azathioprine the cause Nephron 1989 51 509 16
21. Mion F Cloix P Biollot O et al. Venocclusive disease after liver-transplantation-association of acute cellular rejection and toxicity of azathioprine Gastroenterol Clin Biol 1993 17 863 7
22. Read AE Wiesner RH LaBrecque DR et al. Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy Ann Intern Med 1986 104 651 5
23. Stemeck M Wiesner R Ascher N et al. Azathioprine hepatotoxicity after liver transplantation Hepatology 1991 14 806 10
24. DeLeve LD Liver function and hepatotoxicity in cancer In Holland JF Frei E Bast Jr. RC Kufe DW Pollock RE Weichselbaum RR eds Cancer Medicine 5th edn, Vol. 151 Hamilton, ON, Canada BC Dekker 2000 2346 58
25. Walter RB Lukaschek J Renner EL et al. Fatal hepatic veno-occlusive disease associated with terbinafine in a liver transplant recipient J Hepatol 2003 38 373 4
26. Neumeister P Eibl M Zinke-Cerwenka W et al. Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate Ann Hematol 2001 80 119 20
27. Giles FJ Kantarjian HM Komblau SM et al. Mylotarg (Gemtuzumab ozogamicin) therapy is associated with hepatic veno-occlusive disease in patients who have not received stem cell transplantation Cancer 2001 92 406 13
28. Rajvanshi P Shulman HM Sievers EL et al. Hepatic sinusoidal obstruction following Gemtuzumah ozogamicin (Mylotarg) Blood 2002 99 2310 4
29. Giles F Estey E O'Brien S Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia Cancer 2003 98 2095 104
30. Wadleigh M Richardson PG Zahrieh D et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic SCT Blood 2003 102 1578 82
31. Cohen AD Luger SM Sickles C et al. Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease Bone Marrow Transplant 2002 30 23 8
32. Giles FJ Cortes JE Halliburton TA et al. Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions Ann Pharmacother 2003 37 1182 5
33. Lee SW Russell AH Kinney WK Whole abdomen radiotherapy for patients with peritoneal dissemination of endometrial adenocarcinoma Int J Radiat Oncol Biol Phys 2003 56 788 92
34. Uygun K Kocak Z Cicin I Caloglu M Fatal hepatic veno-occlusive disease in an adult patient with Wilms' tumour Clin Oncol (R Coll Radiol) 2003 15 366
35. Kane S Cohen SM Hart J Acute sinusoidal obstruction syndrome after 6-thioguanine therapy for Crohn's disease Inflamm Bowel Dis 2004 10 652 4
36. Praprotnik S Hocevar A Ferlan-Marolt V Tomsic M Azathioprine induced hepatic veno-occlusive disease in systemic lupus erythematosus Lupus 2005 14 493 4
37. Lapierre V Mahe C Auperin A et al. Platelet transfusion containing ABO-incompatible plasma and hepatic veno-occlusive disease after hematopoietic transplantation in young children Transplantation 2005 80 314 9
38. Carreras E Bertz H Arcese W et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party Blood 1998 92 3599 604
39. Jones RJ Lee KSK Beschomer WE et al. Veno-occlusive disease of the liver following bone marrow transplantation Transplantation 1987 44 778 83
40. McDonald GB Hinds MS Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation a cohort study of 355 patients Ann Intern Med 1993 18 255 67
41. McDonald GB Sharma P Matthews DE et al. Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence and predisposing factors Hepatology 1984 4 116 22
42. Essel JH Thompson JM Harman GS et al. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus host disease prophylaxis in patients receiving busulfan/cyclophosphamide Blood 1992 79 2784 8
43. Reiss U Cowan M McMillan A Horn B Hepatic venoocclusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients J Pediatr Hematol Oncol 2002 24 746 50
44. McSweeney PA Niederwieser D Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects Blood 2001 97 3390 400
45. Lee JH Choi SJ Lee JH et al. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation Ann Hematol 2005 84 321 30
46. Kalayoglu-Besisik S Yenerel MN Caliskan Y et al. Time-related changes in the incidence, severity, and clinical outcome of hepatic veno-occlusive disease in hematopoietic stem cell transplantation patients during the past 10 years Transplant Proc 2005 37 2285 9
47. McDonald GB Ren S Bouvier ME et al. Venocclusive disease of the liver and cyclophospha-mide pharmacokinetics: a prospective study in marrow transplant patients Hepatology 1999 30 314A
48. Kallianpur AR Hall LD Yadav M et al. The hemochromatosis C282Y allele: a risk factor for hepatic veno-occlusive disease after hematopoietic stem cell transplantation Bone Marrow Transplant 2005 35 1155 64
49. Frickhofen N Wiesneth M Jainta C et al. Hepatitis C infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation Blood 1994 83 1998 2004
50. Ljungman P Hagglund H Lonnqvist B et al. Hepatitis C virus as a risk factor for the development of veno-occlusive disease of the liver Blood 1994 84 1349 50
51. Strasser SI Myerson D Spurgeon CL et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up Hepatology 1999 29 1893 9
52. Hagglund H Remberger M Klaesson S et al. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation Blood 1998 92 4568 72
53. Shulman HM Fisher LB Schoch HG et al. Venoocclusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms Hepatology 1994 19 1171 80
54. DeLeve LD Dacarbazine toxicity in murine liver cells: a novel model of hepatic endothelial injury and glutathione defense J Pharmacol Exp Ther 1994 268 1261 70
55. DeLeve LD Cellular target of cyclophosphamide toxicity in the murine liver: role of gluta-thione and site of metabolic activation Hepatology 1996 24 830 7
56. DeLeve LD Wang X Kuhlenkamp JF et al. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease Hepatology 1996 23 589 99
57. DeLeve LD McCuskey RS Wang X et al. Characterization of a reproducible rat model of hepatic veno-occlusive disease Hepatology 1999 29 1779 91
58. DeLeve LD Ito Y Machen NW et al. Embolization by sinusoidal lining cells causes the congestion of hepatic venoocclusive disease Gastroenterology 2000 118 A2345
59. DeLeve LD Ito Y Bethea NW et al. Embolization by sinusoidal lining cells obstructs the microcirculation in rat sinusoidal obstruction syndrome Am J Physiol Gastrointest Liver Physiol 2003 284 G1045 52
60. Srivastava A Poonkuzhali B Shaji RV et al. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation Blood 2004 104 1574 7
61. DeLeve LD Wang X Decrease in nitric oxide production contributes to hepatic venoocclusive disease Hepatology 1999 30 218A
62. DeLeve LD Wang X Kanel GC et al. Decreased hepatic nitric oxide production contributes to the development of rat sinusoidal obstruction syndrome Hepatology 2003 38 900 8
63. Brooks SEH Miller CG McKenzie K et al. Acute veno-occlusive disease of the liver Arch Pathol 1970 89 507 20
64. Shulman HM Gown AM Nugent DJ Hepatic veno-occlusive disease after bone marrow transplantation- immunohistochemical identification of the material within occluded central venules Am J Pathol 1987 127 549 58
65. Daly AS Hasegawa WS Lipton JH et al. Transplantation-associated thrombotic microangiopathy is associated with transplantation from unrelated donors, acute graft-versus-host disease and venoocclusive disease of the liver Transfus Apheresis Sci 2002 27 3 12
66. DeLeve DL Wang X Tsai J et al. Sinusoidal obstruction syndrome (Veno-occlusive disease) in the rat is prevented by matrix metalloproteinase inhibition Gastroenterology 2003 125 882 90
67. Iguchi A Kobayashi R Yoshida M et al. Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantation Bone Marrow Transplant 2001 27 1173 80
68. Lee JL Gooley T Bensinger W et al. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome Biol Blood Marrow Transplant 1999 5 306 15
69. Toh HC McAfee SL Sackstein R et al. Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation Bone Marrow Transplant 1999 24 891 5
70. Costa F Choy CG Seiter K. et al. Hepatic outflow obstruction and liver failure due to leukemia cell infiltration in chronic lymphocytic leukemia Leuk Lymphoma 1998 30 403 10
71. Vukelja SJ Baker WJ Jeffreys P et al. Nonbacterial thrombotic endocarditis clinically mimicking veno-occlusive disease of the liver complicating autologous bone marrow transplantation Am J Clin Oncol 1992 15 500 2
72. Blostein MD Paltiel OB Thibault A et al. A comparison of clinical criteria for the diagnosis of veno-occlusive disease of the liver after bone marrow transplantation Bone Marrow Transplant 1992 10 439 43
73. Harper PL Jarvis J Jennings I Luddington R Marcus RE Changes in the natural anticoagulants following bone marrow transplantation Bone Marrow Transplant 1990 5 39 42
74. Gordon B Haire W Kessinger A Duggan M Armitage J High frequency of antithrombin 3 and protein C deficiency following autologous bone marrow transplantation for lymphoma Bone Marrow Transplant 1991 8 497 502
75. Collins P Jone B Uthayakumar S et al. Haemostatic changes in uncomplicated bone marrow transplantation Bone Marrow Transplant 1991 7 Suppl. 2 54
76. Scrobohaci ML Drouet L Monem-MansiI A et al. Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers Thromb Res 1991 63 509 19
77. Aioni EM Bearman SI Krachmalnicoff A et al. Procoagulant imbalance due to low levels of protein C in patients with venocclusive disease (VOD) of the liver after bone marrow transplantation Blood 1991 78 193a
78. Catani L Gugliotta L Mattioli M et al. Hypercoagulability in patients undergoing autologous or allogeneic BMT for hematological malignancies Bone Marrow Transplant 1993 12 253 59
79. Collins P Roderick A O'Brien D et al. Factor VIIa and other hemostatic variables following bone marrow transplantation Thromb Haemost 1994 72 28 2
80. Vannucchi AM Rafanelli D Longo G et al. Early hemostatic alterations following bone marrow transplantation: a prospective study Haematologica 1994 19 519 25
81. Faioni EM Mannucci PM Venocclusive disease of the liver after bone marrow transplantation: the role of hemostasis Leuk Lymphoma 1997 25 233 45
82. Shulman HM McDonald GB Matthews D et al. An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation Gastroenterology 1980 79 1178 91
83. Strasser SI McDonald SJ Schoch HG et al. Severe hepatocellular injury after hematopoietic cell transplant: incidence and etiology in 2136 consecutive patients Hepatology 2000 32 299A
84. Heikinheimo M Halila R Fasth A Serum procollagen type III is an early sensitive marker for veno-occlusive disease of the liver in children undergoing bone marrow transplantation Blood 1994 83 3036 40
85. Eltumi M Trivedi P Hobbs JR et al. Monitoring of venoocclusive disease after bone marrow transplantation by serum aminopropeptide of type III procollagen Lancet 1993 342 518 21
86. Rio B Bauduer F Arrago JP Zittoun R N-terminal peptide of type III procollagen: a marker for the development of hepatic veno-occlusive disease after BMT and a basis for determining the timing of prophylactic heparin Bone Marrow Transplant 1993 11 471 2
87. Tanikawa S Mori S Ohhashi K et al. Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study Bone Marrow Transplant 2000 26 881 6
88. Faioni EM Krachmalnicoff A Bearman SI et al. Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver Blood 1993 81 3458 62
89. Salat C Holler E Kolb HJ et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation Blood 1997 89 2184 8
90. Salat C Holler E Kolb HJ et al. The relevance of plasminogen activator inhibitor 1 (PAI-1) as a marker for the diagnosis of hepatic veno-occlusive disease in patients after bone marrow transplantation Leuk Lymphoma 1999 33 25 32
91. Kaleelrahman M Eaton JD Leeming D et al. Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF) Hematology 2003 8 91 5
92. Park YD Yoshioka A Kawa K et al. Impaired activity of plasma von Willebrand factor-cleaving protease may predict the occurrence of hepatic veno-occlusive disease after stem cell transplantation Bone Marrow Transplant 2002 29 789 94
93. Brown BP Abu-Yousef M Farner R et al. Doppler sonography: a noninvasive method for evaluation of hepatic venocclusive disease AJR 1990 154 721 4
94. Herbetko J Grigg AP Buckley AR Phillips GL Venoocclusive liver disease after bone marrow transplantation: findings at duplex sonography AJR 1992 158 1001 5
95. Nicolau C Bru C Carreras E et al. Sonographic diagnosis and hemodynamic correlation in veno-occlusive disease of the liver J Ultras Med 1993 12 437 40
96. Hommeyer SC Teefey SA Jacobson AF et al. Venocclusive disease of the liver: prospective study of US evaluation Radiology 1992 184 683 6
97. Deeg KH Glockel U Richter R Beck J Diagnosis of veno-occlusive disease of the liver by color-coded Doppler sonography Pediatr Radiol 1993 23 134 6
98. Lassau N Leclere J Auperin A et al. Hepatic venoocclusive disease after myeloablative treatment and bone marrow transplantation: value of gray-scale and Doppler US in 100 patients Radiology 1997 204 545 52
99. McCarville MB Hoffer FA Howard SC et al. Hepatic veno-occlusive disease in children undergoing bone-marrow transplantation: usefulness of sonographic findings Pediatr Radiol 2001 31 102 5
100. Lassau N Auperin A Leclere J et al. Prognostic value of Doppler-ultrasonography in hepatic veno-occlusive disease Transplantation 2002 74 60 6
101. Ghersin E Brook OR Gaitini D Engel A Color Doppler demonstration of segmental portal flow reversal: an early sign of hepatic veno-occlusive disease in an infant J Ultrasound Med 2003 22 1103 6
102. van den Bosch MA van Hoe L MR imaging findings in two patients with hepatic veno-occlusive disease following bone marrow transplantation Eur Radiol 2000 10 1290 3
103. Dumont CH Lambert M Van Beers BE MR imaging findings in a patient with hepatic veno-occlusive disease Acta Gastroenterol Belg 2004 67 236 8
104. Carreras E Granena A Navasa M et al. Transjugular liver biopsy in BMT Bone Marrow Transplant 1993 11 21 6
105. Carreras E Garcia-Pagan JC Bosch J Rozman C Transvenous liver biopsies in marrow transplant recipients Transplantation 1995 60 1375
106. Shulman HM Gooley T Dudley MD et al. Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow recipients Transplantation 1995 59 1015 22
107. Shulman HM Fisher LB Schoch HG Kenne KW Mcdonald GB Venoocclusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms Hepatology 1984 19 1171 80
108. Iqbal M Creger RJ Fox RM et al. Laparoscopic liver biopsy to evaluate hepatic dysfunction in patients with hematologic malignancies: a useful tool to effect changes in management Bone Marrow Transplant 1996 17 655 62
109. Lee RG Vascular disorders In Lee RG ed Diagnostic Liver Pathology Saint Louis Mosby Year Book INC 1994 329 31
110. Bearman SI Avoiding hepatic veno-occlusive disease: what do we know and where are we going Bone Marrow Transplant 2001 27 1113 20
111. Locasciulli A Bacigalupo A Alberti A et al. Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation Transplantation 1989 48 68 72
112. Meresse V Hartmann O Vassal G et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children Bone Marrow Transplant 1992 10 135 41
113. Demirer T Buckner CD Appelbaum FR et al. Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase 1 dose escalation of busulfan based on targeted plasma levels Bone Marrow Transplant 1996 17 491 5
114. Grochow LB Jones RJ Brundrett RB et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation Cancer Chemother Pharmacol 1989 25 55 61
115. Hassan M Ehrsson H Ljungman P Aspects concerning busulfan pharmacokinetics and bio-availability Leuk Lymphoma 1996 22 395 407
116. Ljungman P Hassan M Bekassy AN et al. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients Bone Marrow Transplant 1997 20 909 13
117. McCune JS Gibbs JP Slattery JT Plasma concentration monitoring of busulfan: does it improve clinical outcome Clin Pharmacokinet 2000 39 155 65
118. Schuler U Schroer S Kuhnie A et al. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted Bone Marrow Transplant 1994 14 759 65
119. Slattery JT Clift RA Buckner CD et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation Blood 1997 89 3055 60
120. Slattery JT Risler LJ Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation Ther Drug Monit 1998 20 543 9
121. Kashyap A Wingard J Cagnoni P et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality Biol Blood Marrow Transplant 2002 8 493 500
122. Attal M Huguet F Rubie H et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial Blood 1992 79 2834 40
123. Rosenthal J Sender L Secola R et al. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation Bone Marrow Transplant 1996 18 185 91
124. Or R Nagler A Shpilberg O et al. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients Transplantation 1996 61 1067 71
125. Forrest DL Thompson K Dorcas VG et al. Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study Bone Marrow Transplant 2003 31 1143 9
126. Simon M Hahn T Ford LA et al. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin Bone Marrow Transplant 2001 27 627 33
127. Marsa-Vila L Gorin NC Laporte JP et al. Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation Eur J Haematol 1991 47 346 54
128. Essell JH Schroeder MT Harman GS et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation: a randomized, double-blind, placebo-controlled trial Ann Intern Med 1998 128 975 81
129. Ohashi K Tanabe J Watanabe R et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic venoocclusive disease after stem cell transplantation Am J Hematol 2000 64 32 8
130. Park SH Lee MH Lee H et al. A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation Bone Marrow Transplant 2002 29 137 43
131. Giles F Garcia-Manero G Cortes J et al. Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy Haematologica 2002 87 1114 6
132. Bearman SI Shen DD Hinds MS et al. A phase-I phase-II study of prostaglandin El for the prevention of hepatic venoocclusive disease after bone marrow transplantation Br J Haematol 1993 84 724 30
133. l for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation Br J Haematol 1990 74 277 81
134. Clift RA Bianco JA Appelbaum FR et al. A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation Blood 1993 82 2025 30
135. Ferra C de Sanjose S Lastra CF et al. Pentoxyfylline, ciprofloxacin, and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications Bone Marrow Transplant 1997 20 1075 80
136. Stockschlader M Kalhs P Peters S et al. Intravenous pentoxyfylline failed to prevent transplant-related toxicities in allogeneic bone marrow transplant recipients Bone Marrow Transplant 1993 12 357 62
137. Rubenfeld GD Crawford SW Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: a case for evidence-based guidelines Ann Intern Med 1996 125 625 33
138. Wingard JR Mellits ED Jones RJ et al. Association of hepatic veno-occlusive disease with interstitial pneumonitis in bone marrow recipients Bone Marrow Transplant 1989 4 685 9
139. Zager RA O'Quigley J Zager BK et al. Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients Am J Kidney Dis 1989 3 210 6
140. Baglin TP Veno-occlusive disease of the liver complicating bone marrow transplantation Bone Marrow Transplant 1994 13 1 4
141. Bearman SI Lee JL Baron AE et al. Treatment of hepatic venoocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients Blood 1997 89 1501 6
142. Kulkami S Rodriguez M Lafuente A et al. Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD) Bone Marrow Transplant 1999 23 803 7
143. Partyka J Kim J Tate C Hepatic veno-occlusive disease: a role for tissue plasminogen activator Cancer Control 1994 1 248 51
144. Bajwa RP Cant AJ Abinun M et al. Recombinant tissue plasminogen activator for treatment of hepatic veno-occlusive disease following bone marrow transplantation in children: effectiveness and a scoring system for initiating treatment Bone Marrow Transplant 2003 31 591 7
145. Abbate R Gori AM Martini F et al. Defibrotide reduces monocyte PAI-2 and procoagulant activity Semin Thromb Hemost 1995 21 245 50
146. Berti F Rossoni G Delia Bella D et al. Nitric oxide and prostacyclin influence coronary vasomotor tone in perfused rabbit heart and modulate endothelin-1 activity J Cardiovasc Pharmacol 1993 22 321 6
147. Biagi G Legnani C Rodorigo G et al. Modulation of arachidonate metabolite generation in human blood by oral defibrotide Arzneimittelforschung 1991 41 511 4
148. Bianchi G Barone D Lanzarotti E et al. Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist Eur J Pharmacol 1993 238 327 34
149. Klocking HP Acute t-PA release by defibrotide Thromb Res 1992 66 779 85
150. Lefer AM Aoki N Mulloy D Coronary endothelium-protective effects of defibrotide in ischaemia and reperfusion Naunyn Schmiedebergs Arch Pharmacol 1990 341 246 50
151. Masini E Lupini M Mugnai L et al. Polydeoxyribonucleotides and nitric oxide release from guinea-pig hearts during ischaemia and reperfusion Br J Pharmacol 1995 115 629 35
152. Pellegatta F Lu Y Radaelli A et al. Drug-induced in vitro inhibition of neutrophil-endothelial cell adhesion Br J Pharmacol 1996 118 471 6
153. Coccheri S Biagi G Legnani C et al. Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man Eur J Clin Pharmacol 1988 35 151 6
154. Berti F Rossoni G Biasi G et al. Defibrotide by enhancing prostacyclin generation prevents endothelin-I induced contraction in human saphenous veins Prostaglandins 1990 40 337 50
155. Coccheri S Biagi G Defibrotide Cardiovasc Drug Rev 1991 9 172 96
156. Zhou Q Chu X Ruan C Defibrotide stimulates expression of thrombomodulin in human endothelial cells Thromb Haemost 1994 71 507 10
157. Nicolaides A Novo S eds Advances in Vascular Pathology Amsterdam, The Netherlands Elsevier Science 1997
158. Chopra R Eaton JD Grassi A et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study Br J Haematol 2000 111 1122 9
159. Richardson PG Elias AD Krishnan A et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population Blood 1998 92 737 44
160. Bairey O Kirgner I Yakobi M et al. Clinical severe hepatic venoocclusive disease during induction treatment of acute monoblastic leukemia managed with defibrotide Am J Hematol 2002 69 281 4
161. Salat C Pihusch R Fries S et al. Successful treatment of veno-occlusive disease with defibrotide: a report of two cases Bone Marrow Transplant 1999 23 757 abstract
162. Zinke W Neumeister P Linkesch W Defibrotidean approach in the treatment of severe veno-occlusive disease Bone Marrow Transplant 1999 23 760 abstract
163. Abecasis MM Conceicao Silva JP Ferreira I et al. Defibrotide as salvage therapy for refractory veno-occlusive disease of the liver complicating allogeneic bone marrow transplantation Bone Marrow Transplant 1999 23 843 6
164. Richardson PG Murakami C Jin Z et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome Blood 2002 100 4337 43
165. Saviola A Luppi M Potenza L et al. Late occurrence of hepatic veno-occlusive disease following gemtuzumab ozogamicin: successful treatment with defibrotide Br J Haematol 2003 123 752 3
166. Azoulay D Castaing D Lemoine A et al. Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation Bone Marrow Transplant 2000 25 987 92
167. Rajvanshi P McDonald GB Expanding the use of transjugular intrahepatic portosystemic shunts for veno-occlusive disease Liver Transplant 2001 7 154 9
168. Zenz T Rossle M Bertz H et al. Severe veno-occlusive disease after allogeneic bone marrow or peripheral stem cell transplantation-role of transjugular intrahepatic portosystemic shunt (TIPS) Liver 2001 21 31 6
169. De Larubia J Carral A Montes H et al. Successful treatment of hepatic veno-occlusive disease in a peripheral blood progenitor cell transplant patient with a transjugular intrahepatic portosystemic stent-shunt (TIPS) Haematologica 1996 81 536 9
170. Fried MW Connaghan DG Sharma S et al. Transjugular intrahepatic portosystemic shunt for the management of severe veno-occlusive disease after bone marrow transplantation Hepatology 1996 24 588 91
171. Smith FO Johnson MS Scherer LR et al. Transjugular intrahepatic portosystemic shunting for treatment of severe hepatic veno-occlusive disease Bone Marrow Transplant 1996 18 643 6
172. Nimer SD MilewicZ AL Champlin RE Busuttil RW Successful treatment of hepatic venoocclusive disease in a bone marrow transplant patient with orthotopic liver transplantation Transplantation 1990 49 819 21
173. Rappaport AP Doyle HR Starzl T et al. Orthotopic liver transplantation for lifethreatening veno-occlusive disease of the liver after allogeneic bone marrow transplant Bone Marrow Transplant 1991 8 421 4
174. Kim ID Egawa H Marui Y et al. A successful liver transplantation for refractory hepatic veno-occlusive disease originating from cord blood transplantation Am J Transplant 2002 2 796 800
175. Ringden O Remberger M Lehmann S et al. N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation Bone Marrow Transplant 2000 25 993 6
176. Akyuz C CaClar K Emir S Buyukpamukcu M High-dose methylprednisolone treatment of hepatic veno-occlusive disease in a child with Wilms tumor Pediatr Hematol Oncol 2003 20 345 9
177. Sayer HG Will U Schilling K et al. Hepatic veno-occlusive disease (VOD) with complete occlusion of liver venules after tandem autologous stem cell transplantation: successful treatment with high-dose methylprednisolone and defibrotide J Cancer Res Clin Oncol 2002 128 148 52
178. Tefferi A Kumar S Wolf RC et al. Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation Bone Marrow Transplant 2001 28 997 9
179. Ganem G Saint-Marc Girardin MF Kuentz M et al. Venoocclusive disease of the liver after allogeneic bone marrow transplantation in man Int J Radiat Biol Phys 1988 14 879 84
180. McDonald GB Sharma P Matthews DE et al. The clinical course of 53 patients with veno occlusive disease of the liver after marrow transplantation Transplantation 1985 36 603 8
181. Bearman SI The syndrome of hepatic veno-occlusive disease after marrow transplantation Blood 1995 85 3005 20
182. Lefkowitch JH Bile ductular cholestasis: an ominous histopathologic sign related to sepsis and ''cholangitis lenta'' Hum Pathol 1982 13 19 24